DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
Clinical trial NCT06194695 · UNKNOWN
Trial details
- NCT number
- NCT06194695
- Sponsor
- Ze-yang Ding, MD
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2022-02-01
- Primary completion
- 2024-12-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.